

Targeted treatment with etanercept plus methotrexate for early rheumatoid arthritis patients that have not received any treatment yet. The treatment is rationalised based on the normality of the T-cell stratification.

Submission date	Recruitment status	<input type="checkbox"/> Prospectively registered
16/10/2023	No longer recruiting	<input checked="" type="checkbox"/> Protocol
Registration date	Overall study status	<input checked="" type="checkbox"/> Statistical analysis plan
20/02/2024	Completed	<input checked="" type="checkbox"/> Results
Last Edited	Condition category	<input type="checkbox"/> Individual participant data
26/01/2026	Musculoskeletal Diseases	

Plain English summary of protocol

Background and study aims

Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis. It is a condition where your body's immune system affects the joints, resulting in symptoms of pain with joint swelling. If not adequately controlled, RA results in damage and deformity of joints.

As there is no cure for RA, the current optimal treatment strategy is to start treatment early using a disease modifying anti-rheumatic (DMARD) drug called methotrexate, following a 'Treat to Target' approach. The aim of this approach is to achieve the target of remission (absence of signs and symptoms of disease activity). If this target cannot be achieved in an individual patient (who perhaps has longstanding disease), this approach aims to achieve the best possible state of low disease activity. Treat to target initially requires frequent routine clinical assessments when the disease activity score is calculated. This score guides therapy changes, with the aim of getting the disease activity under control so that the target of remission is reached. The clinical assessments typically involve your overall assessment of disease, counting the number of tender and swollen joints and simple blood tests that measure the level of inflammation present in the blood.

These standard clinical measures can, however be influenced by different factors e.g. pain thresholds or painful joints due to previous damage rather than active disease. Also, milder swelling in the lining of the joint might be difficult to detect by the doctor. Previous studies have shown that patients may deteriorate despite achieving clinical remission, as assessed by these standard clinical measures. Therefore, there is a need for more specific markers for disease activity and to define remission.

Predicting which patients will respond to methotrexate is key to identifying those patients who may benefit from an alternative, more targeted treatment approach in the early stages after

diagnosis i.e. biologic therapy. Multiple predictors of remission have been reported but are not used in routine clinical practice. Diseases like RA are thought to be caused by abnormalities of the cells of the immune system, which are found in the blood (commonly referred to as white blood cells). Abnormalities of one type of cell, the 'naïve T-cell', is key in the development of RA.

Previous research in Leeds has demonstrated that by measuring the number of naïve T-cells in the blood via a simple blood test, we can predict which patients are likely to respond to methotrexate, in those who are newly diagnosed and have not started any form of treatment. Specifically, patients with an abnormally low level of naïve T-cells (compared to a normal reference range in healthy individuals of the same age and gender) did not respond as well to treatment in the study.

This study aims to identify whether measuring a patient's naïve T-cells via a single blood test at diagnosis and before starting any treatment can predict whether they will respond to and do well with standard treatment with methotrexate or not. For those who are predicted to have a poorer response (low naïve T-cells), an alternative and more targeted therapy can be considered without any harmful delay, therefore reducing the risk of disease progression (not current clinical practice).

The information we get might help improve the treatment of people with rheumatoid arthritis. For patients with abnormal T-cells it may be that inflammation can be controlled quicker and more fully with early biologic therapy; to prevent potential deformity and disability.

Who can participate?

Adults over 18 years with a new diagnosis of RA can participate in the study.

What does the study involve?

All participants will be screened and a set of assessments will be performed. Based on all these screening test results, an eligibility assessment will be made and the participants will be randomised to one of the 3 arms in eligibility has been confirmed and then baselined. There will be 3 follow up visits after baseline at 4 weeks, 12 weeks and 24 weeks.

What are the possible benefits and risks of participating?

Benefits: We cannot promise the study will help participants but the information we get might help improve the treatment of people with rheumatoid arthritis. For patients with abnormal T-cells it may be that we can control inflammation quicker and more fully with early biologic therapy; to prevent potential deformity and disability.

Risks/Side effects of Benepali: Benepali®: The study doctor can provide the patient with an information sheet from the manufacturer. The most commonly reported adverse reactions are injection site reactions (such as pain, swelling, itching, reddening and bleeding at the puncture site), infections (such as upper respiratory infections, bronchitis, bladder infections and skin infections), allergic reactions, development of autoantibodies, itching, and fever.

Where is the study run from?

University of Leeds (UK)

When is the study starting and how long is it expected to run for?

February 2020 to July 2025

Who is funding the study?

Samsung Bioepis (South Korea)

Who is the main contact?
Dr Kulveer Mankia, K.S.Mankia@leeds.ac.uk

Contact information

Type(s)

Scientific, Principal investigator

Contact name

Dr Kulveer Mankia

ORCID ID

<https://orcid.org/0000-0002-7945-6582>

Contact details

2nd Floor, Chapel Allerton Hospital
Chapeltown Road
Leeds
United Kingdom
LS7 4SA
+44 (0)113 392 4883
K.S.Mankia@leeds.ac.uk

Type(s)

Public

Contact name

Mrs Neli Stefanova

Contact details

2nd Floor, Chapel Allerton Hospital
Chapeltown Road
Leeds
United Kingdom
LS7 4SA
+44 (0)113 392 4883
n.stefanova@leeds.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)
2016-002344-16

Integrated Research Application System (IRAS)
207599

ClinicalTrials.gov (NCT)
NCT03813771

Protocol serial number

Study information

Scientific Title

Targeted treatment early with etanercept (biosimilar) plus methotrexate or methotrexate with T2T care for DMARD-naïve early RA patients. A prospective, longitudinal cohort study with an embedded pilot randomised controlled trial to assess treatment rationalisation based on naïve CD4+ T-cell stratification.

Acronym

TEEMS

Study objectives

A greater proportion of patients with normal naïve CD4+ T-cell frequencies for their age (Arm A) will achieve clinical remission after 24 weeks of first-line therapy with MTX and T2T care compared to those with abnormally low naïve CD4+ T-cell frequencies (Arm B)

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 21/02/2021, HRA and Health and Care Research Wales (HCRW) (Castlebridge 4, 15-19 Cowbridge Rd E, Cardiff, CF11 9AB, United Kingdom; +44 2920 230457; healthandcareresearch@wales.nhs.uk), ref: 17/YH/0155

Study design

Single centre Phase IV open-label prospective longitudinal cohort study with an embedded pilot randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Rheumatoid arthritis

Interventions

Screening appointment to confirm eligibility, obtain written consent and to collect the necessary clinical and laboratory data as per the study schedule. Following the screening visit, patients will attend a baseline assessment within four weeks.

Patients will be stratified based on their naïve CD4+ T-cell frequency (normal or abnormal based on our pre-defined cut-off values according to age and sex-matched controls).

Patients with a normal T-cell frequency (Arm A) will commence MTX 15 mg/week PO* as per standard T2T practice. Follow-up (4, 12 and 24 weeks), dose escalation of MTX and treatment of flare will also be conducted in line with T2T care.

Patients with an abnormal T-cell frequency will be randomized 1:1 into 2 groups using randomly

permuted block sizes and also followed up as per T2T care:

- The first group (Arm B) will receive MTX 15 mg/week PO*
- The second group (Arm C) will receive MTX 15 mg/week PO* in combination with 50 mg subcutaneous Benepali® administered weekly.

The total duration of the trial is 24 weeks/6 months for all study arms.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Etanercept biosimilar (Benepali), methotrexate

Primary outcome(s)

Number of patients in clinical remission (DAS28ESR ≤2.6) at 24 weeks measured using a combination of: Patient general health assessment on a visual analog scale (0-100 mm), IJA count of 28 joints for swelling and tenderness, and ESR value

Key secondary outcome(s)

1. Number of patients in clinical remission (DAS28ESR ≤2.6) after 12 weeks measured using a combination of: Patient general health assessment on a visual analog scale (0-100 mm), IJA of 28 joints for pain and tenderness, and ESR value
2. Patient-reported outcome measures after 12 weeks & 24 weeks:
 - 2.1. Elderly Mobility Scale (EMS)
 - 2.2. VAS scales from 0 to 100 to measure General health, global pain, disease activity
 - 2.3. HAQ-DI, a measure of the ability to perform daily activities
3. Number of patients in imaging remission (PD=0) after 24 weeks measured using ultrasound scan
4. Number of patients with normal naïve CD4+ T-cells at 24 weeks measured using flow cytometry
5. Cumulative amount of corticosteroid use at 24 weeks usually measured in prednisolone equivalent cumulative dose

Completion date

31/07/2025

Eligibility

Key inclusion criteria

1. Subject has a diagnosis of RA as defined by the new ACR/EULAR 2010 classification criteria
2. Newly diagnosed (within 12 weeks)
3. Active disease at screening (DAS28ESR ≥3.2 or clinical evidence of synovitis i.e. at least one swollen joint)
4. Anti-citrullinated protein antibody (ACPA) positive
5. Male & female subjects ≥18 years old
6. DMARD (disease modifying anti-rheumatic drug) naïve
7. No use of intra-muscular, intra-articular or oral corticosteroids 4 weeks prior to screening
8. All male and female subjects biologically capable of having children must agree to use a

reliable method of contraception for the duration of the study and 24 weeks after the end of the study period. Acceptable methods of contraception are surgical sterilisation, oral, implantable or injectable hormonal methods, intrauterine devices or barrier contraceptives.

9. Patients must have the capacity and be willing to provide written informed consent and comply with the requirements of the protocol

10. Subjects should be deemed to be in good health with respect to clinical examination and screening blood tests, including full blood count (FBC), urea and electrolytes (U&E), and liver functions tests (LFT) – see exclusion criteria for further details.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

90 years

Sex

All

Total final enrolment

106

Key exclusion criteria

1. Use of any additional investigational medications or products within 4 weeks of screening (including prior to screening)
2. Use of intra-muscular/intra-articular or oral corticosteroids within 4 weeks prior to screening
3. Use of more than one NSAID, or increase in dose of NSAIDs within 24 hours before the screening visit.
4. Live vaccine within <4 weeks prior to screening
5. Pregnant/lactating women or planning pregnancy within 24 weeks of last protocol treatment
6. Planned surgery within the study period (requiring omission of study medication > 4 weeks)
7. The presence of other comorbidities, which the physician deems as significant to interfere with evaluation (musculoskeletal condition such as osteoarthritis & fibromyalgia)
8. Diagnosis of another inflammatory arthritis or connective tissue disease (e.g. psoriatic arthritis or Ankylosing spondylitis, primary Sjögren's syndrome, systemic sclerosis, systemic lupus erythematosus, polymyositis)
9. Concomitant severe infection requiring intravenous 4 weeks prior to screening
10. Any contraindication to conventional DMARD's/anti-TNF therapy
11. Patients with abnormal liver function at the time of screening or abnormal blood tests as shown by:
 - 11.1. Aminotransferase (AST) / alanine aminotransferase (ALT) > 3x upper limit of normal (ULN) OR Bilirubin 50µmol/L
 - 11.2. Serum Creatinine > 175 umol/L

- 11.3. eGFR below 30ml/L/min/1.73m²
- 11.4. neutrophils < 2000 x 10⁶/L
- 11.5. Platelets < 125 x 10⁹/L
- 11.6. Haemoglobin < 90 g/L for males and < 85 g/L for females

Date of first enrolment

05/03/2020

Date of final enrolment

08/04/2024

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Leeds Institute of Cardiovascular and Metabolic Medicine

2nd Floor, Chapel Allerton Hospital Chapeltown Road

Leeds

England

LS7 4SA

Sponsor information

Organisation

University of Leeds

ROR

<https://ror.org/024mrxd33>

Funder(s)

Funder type

Industry

Funder Name

Samsung

Alternative Name(s)

Samsung Electronics, Samsung Electronics Co., Ltd., Samsung Group, ,

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

Korea, South

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results		12/01/2026	12/01/2026	No	No
Protocol file	version 8.0	15/05/2024	13/01/2026	No	No
Statistical Analysis Plan	version 3.0		12/01/2026	No	No